BRIEF-Johnson & Johnson Leads With First PARP Inhibitor Combo To Improve Efficacy In Patients With HRR-altered mCSPC

Reuters
03 Jun
BRIEF-Johnson & Johnson Leads With First PARP Inhibitor Combo To Improve Efficacy In Patients With HRR-altered mCSPC

June 3 (Reuters) - Johnson & Johnson JNJ.N:

  • JOHNSON & JOHNSON LEADS WITH FIRST PARP INHIBITOR COMBO TO IMPROVE EFFICACY IN PATIENTS WITH HRR-ALTERED MCSPC

  • JOHNSON & JOHNSON - 50% REDUCTION IN DISEASE PROGRESSION IN BRCA-ALTERED MCSPC

  • JOHNSON & JOHNSON - PHASE 3 AMPLITUDE STUDY SHOWS AKEEGA DELAYS CANCER PROGRESSION

  • JOHNSON & JOHNSON - PHASE 3 AMPLITUDE STUDY MEETS PRIMARY ENDPOINT OF RPFS

Source text: ID:nPnb7FvWVa

Further company coverage: JNJ.N

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10